Vinva Investment Management Ltd Invests $138,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Vinva Investment Management Ltd acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 2,893 shares of the biopharmaceutical company’s stock, valued at approximately $138,000.

Several other large investors have also modified their holdings of HALO. Smartleaf Asset Management LLC increased its position in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares in the last quarter. Louisiana State Employees Retirement System increased its position in Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after purchasing an additional 200 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after purchasing an additional 302 shares in the last quarter. Parkside Financial Bank & Trust increased its position in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its position in Halozyme Therapeutics by 2.4% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 328 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HALO. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Benchmark reiterated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Stock Up 1.3 %

Shares of NASDAQ:HALO opened at $65.16 on Friday. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a fifty day simple moving average of $58.20 and a 200 day simple moving average of $54.76. The firm has a market cap of $8.02 billion, a PE ratio of 19.00, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.